Psilocybin's Potential in Treating Bipolar II Depression Shown by Recent Study

A clinical trial conducted at Sheppard Pratt Hospital in Baltimore and published by the American Medical Association has found that psilocybin-assisted psychotherapy shows efficacy and safety in treating bipolar II depression. The trial involved 15 participants with treatment-resistant BDII depression, and after seven psychotherapy sessions, including one with a single dose of psilocybin, the study subjects displayed strong and persistent antidepressant effects without worsening mood instability or increased suicidality. The study also found improvements in patients' self-reported quality of life scores, and safety metrics such as suicidal ideation and mania did not change significantly. However, the authors caution against casual or unsupported psilocybin use and note that further follow-up studies are needed.